Impact of spondylitis on quality of life, work productivity, and comorbid immune-mediated inflammatory diseases in young and middle-aged patients with axial spondyloarthritis L.V. Ivanova, D.I. Abdulganieva Russian Medical Inquiry, 2026 Aim: to evaluate the prevalence of various spondylitis subtypes based on magnetic resonance imaging (MRI) of the spine in young and middle- aged patients with axial spondyloarthritis (axSpA), and to analyze quality of life (QoL) and work productivity outcomes in patients with and without spondylitis. Materials and Methods: the study enrolled 71 patients with axSpA. Spondylitis subtypes were identified by spinal MRI. Patient-reported outcomes (PROs) were assessed using a combination of questionnaires: QoL was measured with the EQ-5D-5L, EQ-5D-3L, AsQoL, and ASAS Health Index instruments; work productivity was evaluated using the Work Productivity and Activity Impairment (WPAI) questionnaire. Screening for comorbid immune-mediated inflammatory diseases (IMIDs) was performed using the Universal Multidisciplinary Questionnaire for the identification of clinical signs of IMIDs PROs, work productivity parameters, and comorbid IMIDs were compared between patients with and without detected spondylitis. Results: spondylitis was identified in 42 (59.1%) patients, with the most common subtypes being anterior type A spondylitis (40.4%) and posterior type A spondylitis (14.3%). Bone spurs directed toward the anterior longitudinal ligament were found in 13 (30.9%) cases, toward the posterior ligament in 7 (16.7%), anterior corner ankylosis in 8 (19.0%), and posterior corner ankylosis in 5 (11.9%). Assessment of QoL using the AsQoL and ASAS-HI questionnaires revealed no significant differences between patients with and without spondylitis. Regardless of the presence or absence of spondylitis, patients with axSpA were equally likely to be employed: 28 (66.7%) patients with spondylitis and 19 (65.5%) without spondylitis were employed. Patients with axSpA and spondylitis demonstrated reduced productivity indices manifested as significantly greater absenteeism (p<0.05). Analysis of the "Dermatology" and "Gastroenterology" sections of the Universal Questionnaire for comorbid IMID screening in patients with axSpA revealed that 31 (43.67%) cases required exclusion of psoriasis and 36 (50.7%) required exclusion of inflammatory bowel disease (IBD) Conclusion: the findings indicate a high prevalence of inflammatory spinal changes on MRI in axSpA: anterior type A spondylitis was the most common subtype (17 [40.4%] patients), followed somewhat less frequently by posterior type A spondylitis (6 [14.3%]). The study demonstrated a significant reduction in QoL according to the AsQoL and ASAS-HI questionnaires in patients with axSpA, albeit without differences between groups with and without spondylitis. A significant decrease in productivity indices was also demonstrated, manifested as greater absenteeism (p<0.05) in axSpA patients with spondylitis; among patients without Sp, 100% absenteeism was not detected in any case (0%), whereas in those with spondylitis it was observed in 2 (6.9%) cases (p<0.05). A practical application of the Universal Questionnaire for screening of comorbid IMIDs among patients with axSpA is demonstrated. KEYWORDS: ankylosing spondylitis, psoriatic arthritis, sacroiliitis, spondylitis, quality of life. FOR CITATION: Ivanova L.V., Abdulganieva D.I. Impact of spondylitis on quality of life, work productivity, and comorbid immune-mediated inflammatory diseases in young and middle-aged patients with axial spondyloarthritis. Russian Medical Inquiry. 2026;10(3):116–121 (in Russ.). DOI: 10.32364/2587-6821-2026-10-3-2
Intestinal Ultrasound in the Diagnosis of Crohn's Disease of the Ileoanal Pouch: A Clinical Case D. D. Mukhametova, L. R. Ismailova, O. E. Tabakchi, A. F. Shakurov, L. R. Sadykova, R. A. Khramov, E. S. Petrov, A. Kh. Odintsova, D. I. Abdulganieva Russian Journal of Gastroenterology Hepatology Coloproctology, 2026 Aim : to demonstrate the utility of ultrasound in evaluating of Crohn’s disease with multiple extraintestinal manifestations after restorative proctocolectomy. Key points: Patient S., a 40-year-old female, was admitted to the clinic presenting with frequent bloody stools, abdominal pain in left lower quadrant and fever. She had a history of ulcerative colitis diagnosed in 2005. In 2021, the disease was complicated by toxic megacolon requiring a colectomy and an end ileostomy. In 2022, the second stage of surgical treatment was performed: proctectomy with ileal pouch-anal anastomosis. In 2023, the patient developed extraintestinal manifestations: aphthous stomatitis, erythema nodosum, and left ankle arthritis. Examination revealed ultrasound signs of Crohn’s disease: significant thickening of the bowel wall (predominantly of the muscularis propria and submucosa) with loss of wall stratification, as well as pathological vascularization of the ileoanal anastomosis, indicating transmural inflammation. Ileoscopy revealed linear ulcers, and histology showed inflammatory infiltration extending to the muscular layer, confirming the diagnosis of Crohn’s disease. Therapy with ustekinumab was initiated with positive clinical response and disease remission. Conclusion . Ultrasound has revealed signs of transmural inflammation of the ileal pouch and allowed to suspect Crohn’s disease, which has been subsequently confirmed by endoscopic and histological examinations.
The Combination of Anxiety and Depressive Disorders in Patients with Irritable Bowel Syndrome (Literature Review and Expert Council Resolution) V. T. Ivashkin, M. A. Livzan, D. I. Abdulganieva, O. P. Alexeeva, S. A. Alekseenko, N. V. Bakulina, A. Yu. Baranovsky, D. S. Bordin, B. A. Volel, O. Yu. Zolnikova, K. V. Ivashkin, N. V. Korochanskaya, S. N. Mammaev, E. A. Poluektova, D. V. Romanov, V. V. Tsukanov, O. S. Shifrin, S. R. Abdulkhakov, D. N. Andreev, A. G. Beniashvili, Yu. A. Kucheryavyy, I. L. Kliaritskaia, T. L. Lapina, R. V. Maslennikov, R. G. Myazin, M. V. Perekalina, A. M. Sheyanov, A. I. Ulyanin Russian Journal of Gastroenterology Hepatology Coloproctology, 2026 Aim : to review current understanding of the role of intestinal microbiota in the pathogenesis of irritable bowel syndrome (IBS), anxiety and depressive disorders, and to present the materials of the Expert Council, which met on April 19, 2025, in Moscow. Key points. A likely unifying factor in the development of IBS, anxiety, and depressive disorders is a change in the composition of the intestinal microbiota, which causes disruption of neuroendocrine, immune, and metabolic signaling pathways of interaction between the gut and brain (components of the gut-brain axis). The intestinal microbiota plays a coordinating role in maintaining the physiological constancy of these pathways. However, when its composition is disrupted, pathogenic mechanisms are activated, leading to the combined development of both IBS and anxiety and depressive disorders. Recent data have shown that patients with IBS, as well as those suffering from anxiety and depressive disorders, exhibit a unidirectional change in the composition of the intestinal microbiota, characterized by a decrease in the number of Bifidobacterium bacteria , suggesting their key role in the pathogenesis of these diseases. A pathogenetically substantiated therapeutic strategy for the combination of IBS and mental disorders includes modifying the gut microbiota using strain-specific pro biotics containing Bifidobacterium type species. Bifidobacterium longum 35624 and Bifidobacterium longum 1714 strains have demonstrated clinical efficacy in reducing the severity of IBS symptoms, anxiety, and depression. Conclusion . Prescribing a combination of Bifidobacterium longum 35624 and Bifidobacterium longum 1714 probiotic strains to patients with IBS, including those with comorbid mental disorders, is clinically justified. This combination of strains holds promise for inclusion in clinical guidelines for the management of patients with irritable bowel syndrome and mental and behavioral disorders.
On the 100th Anniversary of Valentin E.Anisimov Diana I. Abdulganieva, Grigory P. Arutyunov, Larisa K. Bombina, Dilyara D. Mukhametova, Ilya A. Melentyev Kazan Medical Journal, 2025 The Kazan internal medicine school is famous for its outstanding researchers. Professor Valentin E. Anisimov stands out as a passionate researcher, an experienced teacher and mentor, a scholarly doctor, and an active public figure. Valentin E. Anisimov made a significant contribution to the development of medicine and education both in Kazan and Moscow. He had many areas of expertise, including vitaminology, cardiology, hepatology, and gerontology. His publications covered such important issues as coronary atherosclerosis, dietetics, hormone therapy, and biochemical blood changes and their testing methods. Professor Valentin E. Anisimov is best remembered both as a researcher and a chronicler of the Kazan internal medicine school. He participated in multiple international conferences, shared his achievements and expertise with colleagues. Professor Valentin E. Anisimov played an important role in the training of scientists by teaching students and postgraduates. As a teacher, he was focused on the professional development of recent graduates. His invaluable contributions to the science and history of medicine have gained deep respect in the academic and medical communities.
The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA E. L. Nasonov, V. I. Mazurov, A. M. Lila, T. V. Dubinina, I. Z. Gaidukova, S. A. Lapshina, A. A. Klimenko, D. V. Somov, S. A. Lukyanov, D. M. Chudakov, I. V. Zvyagin, O. V. Britanova, M. A. Korolev, D. I. Abdulganieva, D. G. Krechikova, A. A. Kastanayan, L. V. Eliseeva, R. R. Samigullina, T. V. Povarova, O. V. Antipova, S. A. Smakotina, V. N. Soboleva, O. B. Nesmeyanova, T. V. Plaksina, N. F. Soroka, I. B. Vinogradova, A. P. Rebrov, T. V. Kropotina, A. L. Maslyansky, A. V. Zinkina-Orikhan, Yu. N. Linkova, P. S. Pukhtinskaya, M. A. Morozova, G. A. Vinderskaya Doklady Biochemistry and Biophysics, 2025 The study aims to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of seniprutug (BCD-180) in patients with active radiographic axial spondyloarthritis (r-axSpA, or ankylosing spondylitis). MATERIALS AND METHODS: Two hundred sixty patients with active r-axSpA and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) were randomized into three groups to receive either seniprutug (BCD-180) 5 or 7 mg/kg, or placebo. BCD-180 was administered in the respective group dose using a 0-12-36 week regimen. The placebo group patients were switched to BCD-180 5 mg/kg at Week 24, with therapy continued at Week 36. The primary endpoint was the proportion of patients achieving 40% improvement in the Assessment in Spondyloarthritis International Society (ASAS40) score at Week 24. The secondary endpoints included the proportion of patients achieving an ASAS20/40 response, improvement in 5 of 6 ASAS criteria (ASAS5/6), partial remission according to ASAS, ASDAS-CRP clinically important improvement in (Ankylosing Spondylitis Disease Activity Score with C-reactive protein level, ASDAS-CII) and ASDAS-CRP major improvement (ASDAS-MI). An analysis of changes over time in the disease activity status according to ASDAS-CRP, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index) scores, as well as changes over time in laboratory markers (CRP and erythrocyte sedimentation rate (ESR)) was also conducted. Safety was assessed based on the frequency and profile of adverse events (AE) and adverse reactions (AR). RESULTS: The proportion of patients who achieved an ASAS40 response at Week 24 on seniprutug (BCD-180) at doses of 7 and 5 mg/kg was 51.4 and 40.8%, respectively, compared with 24% in the Placebo group (p = 0.0012 and p = 0.0417, respectively). Analysis of secondary endpoints showed that the efficacy of BCD-180 at both study doses was statistically significantly superior to placebo in patients with r-axSpA at Week 24 in the following respects: reduction in the proportion of subjects with very high disease activity (ASDAS-CRP > 3.5), achieving ASDAS-CII, ASAS20, ASAS5/6 response. A statistically significant decrease in the ASDAS-CRP, BASDAI, BASFI score, as well as CRP and ESR levels was demonstrated. Tolerability of seniprutug therapy was assessed as acceptable. The most common AEs were infusion-related reactions, most of which were mild to moderate according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events) and developed mainly during the first administration. The proportion of patients with detected binding antibodies was 5.1%. No neutralizing antibodies were detected. CONCLUSIONS: Seniprutug (BCD-180) as a therapy for r-axSpA has demonstrated superiority over placebo in the clinical efficacy, a good safety profile and low immunogenicity.
The problem of sarcopenia in patients with inflammatory bowel disease: a review O. E. Akchurina, D. D. Mukhametova, D. I. Abdulganieva Experimental and Clinical Gastroenterology, 2025 Aim: to highlight the problem of sarcopenia among patients with inflammatory bowel diseases (IBD). Key points. In 2019, EWGSOP2 hypothesized that sarcopenia is promoted by many contributing factors including inflammatory bowel diseases (ulcerative colitis and Crohn’s disease). Article presented current hypotheses of the pathogenesis of sarcopenia in patients with IBD, with an emphasis on malnutrition, chronic inflammation, and intestinal dysbiosis. Current methods for diagnosing sarcopenia in patients with IBD are presented. The problem of sarcopenic obesity is separately described. Particular attention is paid to the influence of biological agents on the state of muscles. Although data on sarcopenia in IBD are limited, the available studies suggest the need for a comprehensive approach to assessment, early detection and interventions targeted on inflammation, malnutrition, and muscle wasting. And this is a key component of comprehensive strategies for the management of IBD-associated sarcopenia. Conclusion: The interaction between IBD and sarcopenia represents a significant clinical problem with profound implications for treatment outcomes.
Artificial Intelligence in Ultrasound Diagnosis of Bowel Diseases: Modern Possibilities D. D. Mukhametova, O. E. Akchurina, D. I. Abdulganieva Russian Journal of Gastroenterology Hepatology Coloproctology, 2025 Aim. Review of current achievements, opportunities and challenges in applying artificial intelligence (AI) for analyzing intestinal ultrasound images. Key points. Ultrasound examination is a highly informative, safe, and widely accessible method for bowel pathology diagnosis. The integration of AI, particularly deep learning and radiomics methods, aims to overcome the operator-dependence of ultrasound, standardize diagnosis, and enhance its efficiency. This article reviews the development and validation of AI algorithms for key areas: inflammatory bowel diseases, acute appendicitis, bowel intussusception and colorectal cancer. Limitations and concerns that require resolution for the successful integration of AI into clinical practice are also discussed. Conclusion. The integration of AI into ultrasound diagnosis of bowel diseases has significant potency for improving accuracy, reproducibility, and operational efficiency.
Contrast-enhanced bowel ultrasound in the diagnosis of inflammatory bowel disease: a literature review D. D. Mukhametova, L. R. Ismailova, D. I. Abdulganieva Experimental and Clinical Gastroenterology, 2025 Intestinal ultrasound using microbubble contrast agents or contrast-enhanced ultrasound (CEUS), is promising investigation allowing to perform quantitative and qualitative assessment of inflammatory changes of the intestinal wall such as its thickening, changes of the structure and abnormal microcirculation. This changes correlate with inflammation intensity and help to reveal complications including abscesses, strictures and fistulas in patients with Crohn’s disease. There has been established high sensitivity and moderate specificity of the method in diagnosis of active Inflammatory bowel disease (IBD). Because IBD is a chronic condition requiring frequent visualization to control treatment efficacy which should be safe, not expensive and accurate. CEUS fits these requirements and is not inferior to Computed Tomography and Magnetic Resonance Imaging.
Methodological aspects of Outpatient care module program O. M. Drapkina, S. Yu. Astanina, D. I. Abdulganieva, I. G. Bakulin, I. A. Viktorova, L. Yu. Drozdova, A. V. Kontsevaya, O. Yu. Kuznetsova, M. A. Livzan, O. V. Khodakova, A. I. Chesnikova, N. L. Shaporova, R. N. Shepel Cardiovascular Therapy and Prevention Russian Federation, 2025
Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS L. P. Ananyeva, M. N. Starovoytova, I. Z. Gaydukova, G. V. Lukina, E. V. Zonova, L. V. Eliseeva, G. F. Fatkhullina, D. I. Abdulganieva, D. G. Krechikova, T. V. Kropotina, O. B. Nesmeyanova, I. B. Vinogradova, E. S. Zhugrova, L. V. Ivanova, N. E. Nikulenkova, O. R. Ziganshin, T. V. Plaksina, M. V. Zlobin, Yu. Yu. Grabovetskaya, N. F. Soroka, O. B. Ershova, T. V. Povarova, O. N. Anoshenkova, A. A. Lutsky, A. V. Zinkina-Orikhan, Yu. N. Linkova, E. A. Fokina, A. A. Porozova, A. V. Eremeeva Sovremennaya Revmatologiya, 2025
Russian Cross-disciplinary Consensus on the diagnosis and treatment of spondyloarthritis associated with inflammatory bowel diseases Galina V. Lukina, Oleg V. Knyazev, Elena A. Belousova, Diana I. Abdulganieva, Elena N. Aleksandrova, Igor G. Bakulin, Olga I. Barysheva, Maria А. Borisova, Bella А. Vykova, Alla А. Godzenko, Irina V. Gubonina, Tatiana V. Dubinina, Tatiana N. Zhigalova, Evgeny V. Zhilyaev, Anna V. Kagramanova, Tatiana V. Korotaeva, Alexander V. Kuzin, Maria A. Livzan, Aleksander M. Lila, Vadim I. Mazurov, Evgeny L. Nasonov, Alexander A. Novikov, Marina F. Osipenko, Asfold I. Parfenov, Larisa V. Tarasova, Olga V. Khlynova, Marina V. Shapina, Oksana B. Shchukina, Shandor F. Erdes, Aleksei A. Iakovlev Terapevticheskii Arkhiv, 2025
Small Intestinal Bacterial Overgrowth in Various Specialties of Medical Practice (Literature Review and Expert Council Resolution) V. T. Ivashkin, V. V. Fomin, O. N. Tkacheva, O. S. Medvedev, E. A. Poluektova, D. I. Abdulganieva, S. R. Abdulkhakov, O. P. Alexeeva, S. A. Alekseenko, D. N. Andreev, A. Yu. Baranovsky, M. S. Zharkova, O. Yu. Zolnikova, K. V. Ivashkin, I. L. Kliaritskaia, N. V. Korochanskaya, S. N. Mammaev, R. V. Maslennikov, R. G. Myazin, M. V. Perekalina, A. V. Povtoreyko, A. I. Ulyanin, M. V. Fadeeva, I. B. Khlynov, V. V. Tsukanov, O. S. Shifrin Russian Journal of Gastroenterology Hepatology Coloproctology, 2024
Diagnosis and Treatment of Patients with Autoimmune Hepatitis (Experts’ Agreement) Yu. G. Sandler, E. V. Vinnitskaya, K. L. Raikhelson, K. V. Ivashkin, S. N. Batskikh, E. N. Aleksandrova, D. T. Abdurakhmanov, D. I. Abdulganieva, I. G. Bakulin, A. O. Bueverov, S. L. Vorobyev, O. A. Gerasimova, A. I. Dolgushina, M. S. Zhuravleva, L. Yu. Ilchenko, V. E. Karev, N. V. Korochanskaya, I. L. Kliaritskaia, N. S. Karnaukhov, S. V. Lapin, M. A. Livzan, M. V. Maevskaya, N. V. Marchenko, T. P. Nekrasova, I. G. Nikitin, A. A. Novikov, R. G. Saifutdinov, E. V. Skazyvaeva, V. E. Syutkin, M. K. Prashnova, T. Yu. Khaymenova, S. G. Khomerik Russian Journal of Gastroenterology Hepatology Coloproctology, 2024
CLINICAL GUIDELINES Ulcerative colitis (K51), adults Yu. A. Shelygin, V. T. Ivashkin, E. A. Belousova, I. V. Reshetov, I. V. Maev, S. I. Achkasov, D. I. Abdulganieva, O. A. Alekseeva, I. G. Bakulin, O. Yu. Barysheva, K. V. Bolikhov, A. V. Vardanyan, A. V. Veselov, V. V. Veselov, O. V. Golovenko, I. V. Gubonina, V. L. Denisenko, A. I. Dolgushina, V. N. Kashnikov, O. V. Knyazev, N. V. Kostenko, A. V. Lakhin, P. A. Makarchuk, A. I. Moskalev, B. A. Nanaeva, I. G. Nikitin, N. V. Nikitina, A. Kh. Odintsova, V. V. Omelyanovskiy, A. V. Оshchepkov, V. V. Pavlenko, E. A. Poluektova, S. I. Sitkin, O. I. Sushkov, L. V. Tarasova, A. V. Tkachev, V. M. Тimerbulatov, Yu. B. Uspenskaya, S. A. Frolov, O. V. Khlynova, E. Yu. Chashkova, O. V. Chesnokova, M. V. Shapina, A. A. Sheptulin, O. S. Shifrin, T. V. Shkurko, O. B. Shchukina Koloproktologia, 2023
Consensus on controversial issues of the surgery for Crohn’s disease by Delphi method Yu. A. Shelygin, S. I. Achkasov, I. V. Reshetov, I. V. Mayev, O. M. Drapkina, E. A. Belousova, A. V. Vardanyan, B. A. Nanaeva, D. I. Abdulganieva, L. V. Adamyan, L. S. Namazova-Baranova, A. Yu. Razumovsky, A. Sh. Revishvili, I. E. Khatkov, A. V. Shabunin, M. A. Livzan, A. V. Sazhin, V. M. Timerbulatov, O. V. Khlynova, S. P. Yatsyk, R. A. Abdulkhakov, O. P. Alekseeva, S. A. Alekseenko, I. G. Bakulin, O. Yu. Barysheva, D. A. Blagovestnov, K. V. Bolikhov, V. V. Veselov, Yu. A. Vinogradov, O. V. Golovenko, I. V. Gubonina, A. A. Gulyaev, A. I. Dolgushina, E. Yu. Dyakonova, T. N. Zhigalova, O. Yu. Karpukhin, O. V. Knyazev, N. V. Kostenko, I. D. Loranskaya, A. I. Moskalev, A. H. Odintsova, V. V. Omelyanovsky, M. F. Osipenko, V. V. Pavlenko, E. A. Poluektova, D. E. Popov, G. V. Rodoman, A. M. Segal, S. I. Sitkin, M. I. Skalinskaya, A. N. Surkov, L. V. Tarasova, Yu. B. Uspenskaya, S. A. Frolov, E. Yu. Chashkova, S. G. Shapovalyants, O. S. Shifrin, O. V. Shcherbakova, O. B. Shchukina, T. V. Shkurko, I. V. Nazarov, A. F. Mingazov Koloproktologia, 2023
CLINICAL GUIDELINES: Crohn’s disease (К50), adults Yury A. Shelygin, Vladimir T. Ivashkin, Sergey I. Achkasov, Igor V. Reshetov, Igor V. Maev, Elena A. Belousova, Armen V. Vardanyan, Bella A. Nanaeva, Leila V. Adamyan, Oksana M. Drapkina, Leila S. Namazova-Baranova, Aleksandr Yu. Razumovsky, Amiran Sh. Revishvili, Igor E. Khatkov, Aleksey V. Shabunin, Maria A. Livzan, Aleksandr V. Sazhin, Vil M. Timerbulatov, Olga V. Khlynova, Diana I. Abdulganieva, Rustem A. Abdulkhakov, Timofey L. Aleksandrov, Olga P. Alekseeva, Sergey A. Alekseenko, Ivan S. Anosov, Igor G. Bakulin, Olga Yu. Barysheva, Kirill V. Bolikhov, Viktor V. Veselov, Oleg V. Golovenko, Irina V. Gubonina, Anastasia I. Dolgushina, Tatiana N. Zhigalova, Anna V. Kagramanova, Vladimir N. Kashnikov, Oleg V. Knyazev, Nikolay V. Kostenko, Aleksey A. Likutov, Ekaterina Y. Lomakina, Irina D. Loranskaya, Airat F. Mingazov, Aleksey I. Moskalev, Ilya V. Nazarov, Natalia V. Nikitina, Alfia H. Odintsova, Vitaly V. Omelyanovsky, Marina F. Osipenko, Аndrey V. Оshchepkov, Vladimir V. Pavlenko, Elena A. Poluektova, Grigory V. Rodoman, Anastasia M. Segal, Stanislav I. Sitkin, Maria I. Skalinskaya, Andrey N. Surkov, Oleg I. Sushkov, Larisa V. Tarasova, Yulia B. Uspenskaya, Sergey A. Frolov, Elena Yu. Chashkova, Oleg S. Shifrin, Olga V. Shcherbakova, Oksana B. Shchukina, Tatiana V. Shkurko, P. A. Makarchuk Koloproktologia, 2023
Abnormal liver function tests in patients with COVID-19 Diana I. Abdulganieva, Dilyara D. Mukhametova, Nailya G. Shamsutdinova, Alsou M. Galieva Eksperimental Naya I Klinicheskaya Gastroenterologiya Experimental and Clinical Gastroenterology, 2022
Influence of psychosocial risk factors on the course and prognosis of cardiovascular diseases O. M. Drapkina, A. I. Fedin, O. A. Dorofeeva, V. E. Medvedev, E. N. Kareva, O. N. Dzhioeva, S. G. Kuklin, Е. Yu. Solovieva, D. I. Abdulganieva, Z. F. Kim, M. S. Grigorovich, I. I. Shaposhnik, N. А. Koryagina, S. B. Seredenin Cardiovascular Therapy and Prevention Russian Federation, 2022
Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines V. B. Grinevich, L. B. Lazebnik, Yu. A. Kravchuk, V. G. Radchenko, E. I. Tkachenko, A. M. Pershko, P. V. Seliverstov, C. P. Salikova, K. V. Zhdanov, K. V. Kozlov, V. V. Makienko, I. V. Potapova, E. S. Ivanyuk, D. V. Egorov, E. I. Sas, M. D. Korzheva, N. M. Kozlova, A. K. Ratnikova, V. A. Ratnikov, S. I. Sitkin, L. Z. Bolieva, C. V. Turkina, D. I. Abdulganieva, T. V. Ermolova, S. A. Kozhevnikova, L. V. Tarasova, R. G. Myazin, N. M. Khomeriki, T. L. Pilat, L. P. Kuzmina, R. A. Khanferyan, V. P. Novikova, A. V. Polunina, A. I. Khavkin Eksperimental Naya I Klinicheskaya Gastroenterologiya Experimental and Clinical Gastroenterology, 2022
Clinical and sonographic characteristics of enthesis lesions in inflammatory bowel disease Kazan State Medical University, Kazan, Russian Federation, G.R. Gainullina, E.R. Kirillova, Kazan State Medical University, Kazan, Russian Federation, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation, A.Kh. Odintsova, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation, D.I. Abdulganieva, Kazan State Medical University, Kazan, Russian Federat, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation Russian Medical Inquiry, 2021
Enthesopathy in spondyloarthritis: The literature review D. I. Abdulganieva, E. R. Kirillova, I. F. Fairushina, G. R. Gaynullina, R. Z. Abdrakipov, R. G. Mukhina, E. I. Mukhametshina Nauchno Prakticheskaya Revmatologiya, 2021
Specificity of treatment response to infliximab in patients with inflammatory bowel disease and ankylosing spondylitis Kazan State Medical University, Kazan, Russian Federation, T.Yu. Nuriakhmetova, I.Kh. Valeeva, Kazan State Medical University, Kazan, Russian Federation, Ya.O Shevnina, N.A. Semashko Republican Clinical Hospital, Simferopol, Russian Federation, A.V. Petrov, V.I. Vernadskiy Crymean State University, Simferopol, Russian Federation, A.Kh. Odintsova, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation, R.Z. Abdrakipov, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation, T.B. Sibgatullin, Kazan State University, Kazan, Russian Federation, A.G. Vasil’ev, City Clinical Hospital No. 7, Kazan, Russian Federation, D.I. Abdulganieva, Kazan State Medical University, Kazan, Russian Federation Russian Medical Inquiry, 2021
Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version L. B. Lazebnik, E. V. Golovanova, S. V. Turkina, K. L. Raikhelson, S. V. Okovityy, O. M. Drapkina, I. V. Maev, A. I. Martynov, G. E. Roitberg, O. V. Khlynova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, I. G. Bakulin, N. V. Bakulina, A. O. Bueverov, E. V. Vinitskaya, G. V. Volynets, E. Yu. Eremina, V. B. Grinevich, A. I. Dolgushina, A. N. Kazyulin, E. I. Kashkina, I. V. Kozlova, Yu. V. Konev, N. V. Korochanskaya, Yu. A. Kravchuk, E. D. Li, I. D. Loranskaya, V. M. Makhov, S. N. Mekhtiev, V. P. Novikova, O. D. Ostroumova, Ch. S. Pavlov, V. G. Radchenko, A. A. Samsonov, A. S. Sarsenbaeva, R. G. Sayfutdinov, P. V. Seliverstov, S. I. Sitkin, O. V. Stefanyuk, L. V. Tarasova, E. I. Tkachenko, Yu. P. Uspensky, Yu. A. Fominykh, A. I. Khavkin, Yu. V. Tsyganova, O. O. Sharhun Eksperimental Naya I Klinicheskaya Gastroenterologiya Experimental and Clinical Gastroenterology, 2021
Analysis of the results of tofacitinib therapy in real clinical practice according to the all-russian arthritis registry (orel) A. S. Avdeeva, A. S. Misiyuk, A. M. Satybaldyev, G. V. Lukina, V. N. Sorotskaya, E. V. Zhilyaev, A. R. Babaeva, A. A. Baranov, V. I. Mazurov, I. N. Shendrygin, T. S. Salnikova, L. A. Knyazeva, D. G. Krechikova, R. R. Samigullina, I. Z. Gaidukova, D. I. Abdulganieva, I. N. Kushnir, O. N. Anoshenkova, N. A. Lapkina, E. A. Koshkarova, A. M. Lila, E. L. Nasonov Nauchno Prakticheskaya Revmatologiya, 2020
EXPERIENCE OF TOFACITINIB USING IN THERAPY OF ULCERATIVE COLITIS IN REAL CLINICAL PRACTICE E. A. Belousova, Вю I. Abdulganieva, O. P. Alekseeva, I. G. Bakulin, O. V. Vasilyeva, A. V. Veselov, A. V. Kagramanova, V. N. Kashnikov, O. V. Knyazev, M. V. Koroleva, N. V. Nikitina, N. N. Nikolaeva, A. V. Tkachev, T. Yu. Chashkova, M. V. Shapina Koloproktologia, 2019
PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ULCERATIVE COLITIS V. T. Ivashkin, Yu. A. Shelygin, E. A. Belousova, D. I. Abdulganieva, O. A. Alekseeva, S. I. Achkasov, E. Yu. Valuiskikh, A. V. Vardanyan, A. V. Veselov, V. V. Veselov, O. V. Golovenko, I. V. Gubonina, T. N. Zhigalova, V. N. Kashnikov, O. V. Knyazev, P. A. Makarchuk, A. I. Moskaliev, B. A. Nanaeva, A. A. Nizov, N. V. Nikitina, N. N. Nikolaeva, V. V. Pavlenko, E. A. Poluektova, I. O. Svetlova, L. V. Tarasova, A. V. Tkachev, S. A. Frolov, O. V. Khlynova, E. Yu. Chashkova, M. V. Shapina, A. A. Sheptulin, O. S. Shifrin, O. B. Shchukina Koloproktologia, 2019
S. S. Zimnitsky--an outstanding representative of Kazantherapeutic school (For the 200th anniversary of the Kazan state medical University) Klinicheskaia Meditsina, 2015
Fecal neutrophil gelatinase-associated lipocalin is a surrogate marker of inflammation in inflammatory bowel disease Ksperimental Naia I Klinicheskaia Gastronterologiia Experimental Clinical Gastroenterology, 2014
The history of the Kazan School of Therapists (on the occasion of the 200th anniversary of the Kazan State Medical University) Terapevticheskii Arkhiv, 2014
[Comparative analysis of quality of life and psychological features of patients with ulcerative colitis and Crohn's disease]. Ksperimental Nai Combining Double Inverted Breve A I Klinicheskai Combining Double Inverted Breve A Gastronterologii Combining Double Inverted Breve A Experimental Clinical Gastroenterology, 2013
[Dynamics of intragastric acidity in patients with osteoarthritis and rheumatoid arthritis during therapy with diclofenac sodium]. Ksperimental Naia I Klinicheskaia Gastronterologiia Experimental Clinical Gastroenterology, 2011
[On the history of studies on gastric acid-producing function]. Klinicheskaia Meditsina, 2011
